Radiance Biopharma develops next-generation antibody-drug conjugates (ADCs), including bispecific ADCs that target HER2 and TROP-2, to enhance the precision of cancer therapeutics. The company focuses on addressing high unmet medical needs in oncology by delivering targeted treatments that minimize damage to healthy tissues while maximizing therapeutic efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers express tumor-associated antigens, but traditional chemotherapies lack specificity, leading to systemic toxicity and off-target effects. Targeted therapies like monoclonal antibodies can improve specificity, but may lack sufficient potency to eradicate tumors, especially in heterogeneous or drug-resistant cancers.
Solution
Radiance Biopharma develops next-generation antibody-drug conjugates (ADCs) designed to selectively target and eliminate cancer cells while sparing healthy tissue. Their pipeline includes bispecific ADCs that simultaneously bind two different tumor-associated antigens, enhancing target specificity and internalization. The ADCs utilize protease-cleavable linkers to release a potent cytotoxic payload, monomethyl auristatin E (MMAE), specifically within the tumor microenvironment. This approach aims to improve therapeutic efficacy and reduce systemic toxicity compared to conventional chemotherapy or first-generation ADCs.
Target Audience
The primary target audience includes patients with solid tumors and hematologic malignancies who have limited treatment options or have developed resistance to existing therapies.
Features
- RB-201: A bispecific ADC targeting both HER2 and TROP-2, designed for enhanced binding and internalization in tumors expressing either or both antigens.
- RB-164: A next-generation ADC targeting ROR-1, utilizing proprietary conjugation and linker technologies for optimized drug delivery.
- RB-203: A monoclonal antibody recognizing membrane Hsp70, which is selectively expressed on the surface of tumor cells but not normal cells.
- ADCs utilize a protease-cleavable linker, designed for payload release within the tumor microenvironment, minimizing systemic exposure.
- MMAE payload: A potent microtubule inhibitor that induces cell cycle arrest and apoptosis in targeted cancer cells.